Tandem Diabetes Care enters its third-quarter report with a story that has gotten better on almost every measure except the one that shows up first on the income statement. Margins are climbing, new patient starts have picked up and the product pipeline is crowded with catalysts. Yet reported sales growth remains stuck in the mid-single digits because the company is deliberately moving customers toward a pharmacy, pay-as-you-go model that trades upfront pump revenue for recurring supply income. Thursday's numbers should show whether that trade is still paying off fast enough to justify the patience.

Wall Street expects a loss of 27 cents per share on revenue of about $265.3 million. That works out to sales growth of roughly 6.4% from a year ago and a narrower loss than the 31 cents posted in both the prior quarter and the year-ago period. Sequentially, the revenue target implies about $11 million of improvement from the second quarter, which is meaningful for a company absorbing a pump revenue headwind of around $8 million a quarter from zero-upfront pharmacy placements. Management reaffirmed full-year revenue guidance of $1.065 billion to $1.085 billion, and the consensus of $1.08 billion sits near the top of that range. In other words, analysts are already leaning toward the optimistic end of the outlook, which leaves little room for a soft quarter.

The prior call set up several specific tests. Management guided third-quarter gross margin to about 56%, down a point from the second quarter's 57%, and adjusted EBITDA margin to around 2% as operating spending rises. Hitting or beating those marks would confirm that the margin gains from pharmacy pricing and Mobi cost scaling are durable rather than a one-quarter peak. Pharmacy penetration is the other key gauge. It reached about 10% of US sales last quarter, up from 6% in the first quarter, and the company is targeting roughly 20% of pump shipments and 10% of the installed base by year end. Continued progress toward those goals, along with formulary coverage holding above 45%, would validate the channel strategy. A stall would raise questions about the learning curve.

Demand is the less settled part of the narrative. US new starts jumped more than 20% sequentially last quarter, but they were nearly flat year over year, falling short of the return-to-growth tone set earlier in the year. A genuine year-over-year increase in new starts, ideally still led by conversions from multiple daily injections, would be the clearest sign that the claimed inflection is real. Supply is the swing factor working against that. The infusion set shortage peaked in the second quarter by management's account and was expected to ease through the back half, helped by the AutoSoft Plus rollout. Any lingering drag on US or international supply sales would hit the recurring revenue stream the whole pharmacy thesis depends on. Investors should also want an update on the Mobi Tubeless 510(k), since a scaled launch was targeted for the second half, and on the CMS C-peptide decision that was due in August.

The market has rewarded the story so far. Shares have gained about 13% since the last report while the S&P 500 was essentially flat, and the stock trades above its 200-day moving average near $19. Still, at $19.68 it sits well below the post-earnings high of $24.81, suggesting some of the early enthusiasm has faded. Sentiment has cooled notably as well, with bearish readings rising to 31.5% from 11.8% heading into the prior quarter.

That skepticism frames the central question. Tandem does not need a dramatic beat, but it does need to show that margins are holding near guidance, that pharmacy adoption keeps compounding and that new starts are finally growing year over year. If those pieces line up while the infusion set squeeze eases, the reaffirmed outlook looks conservative. If they do not, a consensus already parked near the high end of guidance could prove too ambitious.